--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-24-016864" form_type: "8-K/A" ticker: "AWHL" cik: "0000926617" company_name: "Aspira Women's Health Inc." filed_at: "2024-01-26T23:59:59+00:00" generated_at: "2026-06-06T17:11:46.270583+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.75 calibrated_materiality_score: 0.75 confidence: "high" source: SEC EDGAR --- # Aspira Women's Health raises ~$5.5M in offering; warrants repriced, preliminary cash ~$2.6M ## Summary - Raised ~$5.5M gross via registered direct offering and concurrent private placement at $3.50/share. - Issued 1.371M shares, 200K pre-funded warrants ($0.0001 exercise), and 1.571M purchase warrants ($4.13 exercise). - Existing 366,664 warrants amended: exercise price cut from $13.20 to $4.13, term extended to Jan. 26, 2029. - Preliminary cash and equivalents ~$2.6M as of Dec. 31, 2023; excluding restricted cash of $0.3M. ## SEC filing metadata - accession: 0001193125-24-016864 - form_type: 8-K/A - ticker: AWHL - cik: 0000926617 - company_name: Aspira Women's Health Inc. - filed_at: 2024-01-26T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.75 - calibrated_materiality_score: 0.75 - confidence: high - sec_items: 1.01, 2.02, 3.02, 3.03, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/926617/000119312524016864/0001193125-24-016864-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926617/000119312524016864/d699303d8ka.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-24-016864 - JSON: https://secwatch.observer/filing/0001193125-24-016864.json - Plain text: https://secwatch.observer/filing/0001193125-24-016864.txt ## Key facts - Material Agreements Aspira Women's Health Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at Placement agent fee of 7.0% of gross proceeds from the offering (effective 2024-01-24). - Action: entry - Agreement: underwriting - Counterparty: A.G.P./Alliance Global Partners - Value: Placement agent fee of 7.0% of gross proceeds from the offering - Effective: 2024-01-24 source text: On January 24, 2024, Aspira Women’s Health Inc. (the “Company” or “Aspira”) entered into a placement agency agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (“AGP”) and a securities purchase agreement (the “Securities Purchase Agreement,” and together with the Placement Agency Agreement, the “Agreements”) with a single healthcare focused institutional investor alongside participation from Nicole Sandford, CEO of Aspira, as well as certain existing shareholders of the Company (collectively, the “Purchasers”), relating to the issuance and sale of 1,371,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and pre-funded warrants to purchase 200,000 shares of Common Stock (the “Pre-Funded Warrants”), in a registered direct offering, together with accompanying warrants to purchase 1,571,000 shares of Common Stock (the “Purchase Warrants”, and together with the Pre-Funded Warrants, the “Warrants”) in a concurrent private evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000119312524016864/0001193125-24-016864-index.htm - Material Agreements Aspira Women's Health Inc. entered into Securities Purchase Agreement with single healthcare focused institutional investor, Nicole Sandford, and certain existing shareholders valued at Issuance of 1,368,600 shares at $3.50 per share and 2,400 shares at $4.255 per share, plus warrants; (effective 2024-01-24). - Action: entry - Agreement: equity purchase - Counterparty: single healthcare focused institutional investor, Nicole Sandford, and certain existing shareholders - Value: Issuance of 1,368,600 shares at $3.50 per share and 2,400 shares at $4.255 per share, plus warrants; - Effective: 2024-01-24 source text: On January 24, 2024, Aspira Women’s Health Inc. (the “Company” or “Aspira”) entered into a placement agency agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (“AGP”) and a securities purchase agreement (the “Securities Purchase Agreement,” and together with the Placement Agency Agreement, the “Agreements”) with a single healthcare focused institutional investor alongside participation from Nicole Sandford, CEO of Aspira, as well as certain existing shareholders of the Company (collectively, the “Purchasers”), relating to the issuance and sale of 1,371,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and pre-funded warrants to purchase 200,000 shares of Common Stock (the “Pre-Funded Warrants”), in a registered direct offering, together with accompanying warrants to purchase 1,571,000 shares of Common Stock (the “Purchase Warrants”, and together with the Pre-Funded Warrants, the “Warrants”) in a concurrent private evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000119312524016864/0001193125-24-016864-index.htm - Material Agreements Aspira Women's Health Inc. amended Existing Warrants Amendment Agreement with holders of existing warrants valued at Amend existing warrants covering 366,664 shares: reduce exercise price from $13.20 to $4.13 per shar (effective 2024-01-26). - Action: amendment - Counterparty: holders of existing warrants - Value: Amend existing warrants covering 366,664 shares: reduce exercise price from $13.20 to $4.13 per shar - Effective: 2024-01-26 source text: The Company has also agreed that certain existing warrants to purchase up to an aggregate of 366,664 shares at an exercise price of $13.20 per share and a termination date of August 25, 2027, will be amended, effective upon the closing of the Offering, so that the amended warrants will have a reduced exercise price of $4.13 per share and a new termination date of January 26, 2029. evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000119312524016864/0001193125-24-016864-index.htm - Material Agreements Aspira Women's Health Inc. entered into Form of Purchase Warrant with single healthcare focused institutional investor and others valued at Warrant to purchase up to 1,571,000 shares at $4.13 per share; exercisable six months after issuance (effective 2024-01-24). - Action: entry - Agreement: equity purchase - Counterparty: single healthcare focused institutional investor and others - Value: Warrant to purchase up to 1,571,000 shares at $4.13 per share; exercisable six months after issuance - Effective: 2024-01-24 source text: The Purchase Warrants will have an exercise price of $4.13 per share, and will be exercisable beginning six months after issuance and will expire 5 years from the initial exercise date. evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000119312524016864/0001193125-24-016864-index.htm - Material Agreements Aspira Women's Health Inc. entered into Form of Pre-Funded Warrant with single healthcare focused institutional investor and others valued at Pre-funded warrant to purchase up to 200,000 shares at $0.0001 exercise price; exercisable at any ti (effective 2024-01-24). - Action: entry - Agreement: equity purchase - Counterparty: single healthcare focused institutional investor and others - Value: Pre-funded warrant to purchase up to 200,000 shares at $0.0001 exercise price; exercisable at any ti - Effective: 2024-01-24 source text: g descriptions of the terms of the Placement Agency Agreement, the Securities Purchase Agreement, Pre-Funded Warrants and Purchase Warrants are each qualified in their entirety by reference to the Placement Agency Agreement, the Securities Purchase Agreement, form of Pre-Funded Warrant and form of Purchase Warrant, respectively, which are attached as Exhibit 1.1, Exhibit 10.1, Exhibit 4.1 and Exhibit 4.2 hereto, respectively, and incorporated by reference herein. evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000119312524016864/0001193125-24-016864-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.